The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Regorafenib is a multi-kinase inhibitor and the second-line treatment for HCC. Since the PI3K/Akt/mTOR signaling pathway is dysregulated in HCC, we evaluated the therapeutic effects of regorafenib combined with a dual...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Cheng-Chan, Huang, Sung-Ying, Chang, Shu-Fang, Liao, Kuan-Fu, Chiu, Sheng-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287658/
https://www.ncbi.nlm.nih.gov/pubmed/32466169
http://dx.doi.org/10.3390/molecules25102454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287658/
https://www.ncbi.nlm.nih.gov/pubmed/32466169
http://dx.doi.org/10.3390/molecules25102454

Ejemplares similares